AbbVie bets on dual-target cancer therapies Disco deal

This site is intended for healthcare professionals

AbbVie bets on dual-target cancer therapies in Disco research deal

Author:
People in laboratory

Key Summary:

  • AbbVie will pay Disco Pharmaceuticals $40m upfront to discover new treatments for solid tumours.
  • The experimental therapies are designed to recognise cancer cells using two targets together.
  • Disco could receive up to $2.5bn in further payments, plus royalties on worldwide sales.

AbbVie has struck a deal with Germany’s Disco Pharmaceuticals to develop a new generation of cancer therapies designed to distinguish tumour cells from healthy tissue.

The agreement, which will focus on solid tumours in patients that have few other treatment options, gives AbbVie the option to take exclusive licences on selected programmes once Disco completes specified research.

It will see privately held biotech Disco receive $40m upfront with the opportunity to earn up to $2.5bn in further payments tied to licensing options, development and other milestones.

Using two targets to recognise cancer cells

Bispecific therapies are designed to bind two targets. The approach AbbVie and Disco are pursuing, known as ‘AND-gating’, requires both target proteins to be present together for the intended effect.

The idea is that a pair of proteins may distinguish a tumour cell from healthy tissue even when one of those proteins also appears on healthy cells and could help reduce damage to healthy tissue, a challenge in developing treatments for solid tumours.

Disco’s current approach maps the proteins on the surface of cancer cells to find pairs that could serve as targets. The company is using it to design antibody-drug conjugates, which deliver a drug payload to targeted cells, and T-cell engagers, which direct immune cells towards a tumour.

The collaboration is at the discovery stage, and whether the approach can spare healthy tissue while retaining its effect against tumours still remains to be demonstrated in patients.

AbbVie builds on its bispecific cancer portfolio

The deal follows AbbVie’s January agreement with China’s RemeGen, under which it paid $650m upfront for rights outside China to a bispecific treatment for solid tumours.

With the Disco partnership, AbbVie is investing earlier in the discovery process and can decide which programmes to license once the agreed research is complete.

Mark Manfredi, Ph.D., CEO of DISCO Pharmaceuticals  said: “The collaboration with AbbVie represents an important opportunity to deliver the next generation of precision medicines to patients with difficult-to-treat solid tumours.”

Ajla Hrle, Ph.D., CBO of DISCO Pharmaceuticals added: “We look forward to working together with AbbVie towards the shared goal of creating transformative therapeutics for patients. This collaboration further underscores the potential of our differentiated platform and complements our portfolio of internal and partnered pipeline programs,” added.

AbbVie’s agreement with Disco is the latest in a series of pharma licensing deals announced this week and follows Pfizer’s agreement to pay China’s Starna Therapeutics $330m upfront for rights to three experimental CAR-T programmes for autoimmune diseases.

Featured image: SiphosethuFan/peopleimages.com on AdobeStock

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Rate this content's potential impact on patient outcomes

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this content.